U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 bln



(Reuters) – The United States has signed contracts worth about $1 billion for doses of the antibody-based COVID-19 treatment from Britain’s GSK (GSK.L) and U.S.-based Vir Biotechnology (VIR.O), as countries seek to secure promising options beyond vaccines.

The drugmakers said on Wednesday the U.S. orders bring the total number of doses to be supplied to more than 750,000 globally, without specifying how many doses of the treatment, sotrovimab, the U.S. government had signed up for.

However, other public deals for the drug include 10,000 doses for Canada and up to 220,000 doses for the European Union. Values of those orders have not been disclosed.

U.S. deliveries of the treatment, branded Xevudy, are expected by Dec. 17 and the government will also have an option to buy more doses through March 2022, GSK and Vir said in their joint statement.

Reuters source: